Skip to main navigation
logo

Investor Relations

  • Overview
  • News & Events
    • News Releases
    • Events and Presentations
  • Corporate Governance
    • Governance Overview
    • Executive Leadership
    • Board of Directors
    • Committee Composition
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financials & Filings
    • SEC Filings
  • Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR

News releases

10 Jan / 23
Absci First to Create and Validate De Novo Antibodies with Zero-Shot Generative AI
This breakthrough unlocks the potential to accelerate time to clinic by over 50% and increase probability of success in the clinic Creating antibodies in silico with generative AI represents a major industry breakthrough on the path to fully de novo antibody design and Absci’s vision to deliver
08 Jan / 23
Absci to Participate in the 41st Annual J.P. Morgan Healthcare Conference
VANCOUVER, Wash. and NEW YORK, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 41 st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Featured Pages

Stock information
Stock information
Governance
Governance
SEC filings
SEC filings
Investor FAQs
Investor FAQs

Investor Tools

  • RSS Feeds
  • Print Page
  • Email Alerts
  • Contact IR

© 2023 Absci Corp.     All rights reserved.

  • Facebook
  • Twitter
  • LinkedIn
  • Google+